27680006|t|Hematological, biochemical, and toxicopathic effects of subchronic acetamiprid toxicity in Wistar rats
27680006|a|Acetamiprid is one of the most widely used neonicotinoids. This study investigates toxic effects of repeated oral administration of three doses of acetamiprid (1/20, 1/10, and 1/5 of LD50) during 60 days. For this, male Wistar rats were divided into four different groups. Hematological, biochemical, and toxicopathic effects of acetamiprid were evaluated. According to the results, a significant decrease in the body weight gain at the highest dose 1/5 of LD50 of acetamiprid was noticed. An increase in the relative liver weight was also observed at this dose level. The hematological constituents were affected. A significant decrease in RBC, HGB, and HCT in rats treated with higher doses of acetamiprid (1/10 and 1/5 of LD50) was noted. However, a significant increase in WBC and PLT were observed at the same doses. Furthermore, acetamiprid induced liver toxicity measured by the increased activities of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphates (ALPs), and lactate dehydrogenase (LDH) which may be due to the loss of hepatic membrane architecture and hepatocellular damage. In addition, exposure to acetamiprid resulted in a significant decrease in the levels of superoxide dismutase and catalase activities (p â‰¤ 0.01) with concomitant increase in lipid peroxidation in rat liver. These findings highlight the subchronic hepatotoxicity of acetamiprid.
27680006	0	13	Hematological	T033	UMLS:C0243095
27680006	15	26	biochemical	T033	UMLS:C0243095
27680006	32	52	toxicopathic effects	T033	UMLS:C0243095
27680006	67	78	acetamiprid	T103	UMLS:C1142891
27680006	79	87	toxicity	T037	UMLS:C0600688
27680006	91	102	Wistar rats	T204	UMLS:C0034716
27680006	103	114	Acetamiprid	T103	UMLS:C1142891
27680006	146	160	neonicotinoids	T103	UMLS:C1997222
27680006	186	199	toxic effects	T037	UMLS:C0600688
27680006	250	261	acetamiprid	T103	UMLS:C1142891
27680006	323	334	Wistar rats	T204	UMLS:C0034716
27680006	376	389	Hematological	T033	UMLS:C0243095
27680006	391	402	biochemical	T033	UMLS:C0243095
27680006	408	428	toxicopathic effects	T033	UMLS:C0243095
27680006	432	443	acetamiprid	T103	UMLS:C1142891
27680006	449	458	evaluated	T058	UMLS:C0220825
27680006	516	532	body weight gain	T033	UMLS:C0043094
27680006	568	579	acetamiprid	T103	UMLS:C1142891
27680006	621	626	liver	T017	UMLS:C0023884
27680006	744	747	RBC	T017	UMLS:C0014792
27680006	749	752	HGB	T103	UMLS:C0019046
27680006	758	761	HCT	T033	UMLS:C0518014
27680006	765	769	rats	T204	UMLS:C0034716
27680006	799	810	acetamiprid	T103	UMLS:C1142891
27680006	880	883	WBC	T017	UMLS:C0023516
27680006	888	891	PLT	T017	UMLS:C0005821
27680006	938	949	acetamiprid	T103	UMLS:C1142891
27680006	950	972	induced liver toxicity	T038	UMLS:C4279912
27680006	999	1009	activities	T038	UMLS:C0243102
27680006	1013	1039	aspartate aminotransferase	T103	UMLS:C0004002
27680006	1041	1044	AST	T103	UMLS:C0004002
27680006	1047	1071	alanine aminotransferase	T103	UMLS:C0001899
27680006	1073	1076	ALT	T103	UMLS:C0001899
27680006	1079	1098	alkaline phosphates	T103	UMLS:C0002059
27680006	1100	1104	ALPs	T103	UMLS:C0002059
27680006	1111	1132	lactate dehydrogenase	T103	UMLS:C0022917
27680006	1134	1137	LDH	T103	UMLS:C0022917
27680006	1171	1200	hepatic membrane architecture	T017	UMLS:C2331083
27680006	1205	1226	hepatocellular damage	T038	UMLS:C0151763
27680006	1253	1264	acetamiprid	T103	UMLS:C1142891
27680006	1317	1337	superoxide dismutase	T103	UMLS:C0038838
27680006	1342	1350	catalase	T103	UMLS:C0007367
27680006	1351	1361	activities	T038	UMLS:C0243102
27680006	1402	1420	lipid peroxidation	T038	UMLS:C0023775
27680006	1424	1427	rat	T204	UMLS:C0034716
27680006	1428	1433	liver	T017	UMLS:C0023884
27680006	1441	1449	findings	T033	UMLS:C0243095
27680006	1475	1489	hepatotoxicity	T037	UMLS:C0235378
27680006	1493	1504	acetamiprid	T103	UMLS:C1142891